JP2013533846A - 抗転移化合物 - Google Patents

抗転移化合物 Download PDF

Info

Publication number
JP2013533846A
JP2013533846A JP2013503921A JP2013503921A JP2013533846A JP 2013533846 A JP2013533846 A JP 2013533846A JP 2013503921 A JP2013503921 A JP 2013503921A JP 2013503921 A JP2013503921 A JP 2013503921A JP 2013533846 A JP2013533846 A JP 2013533846A
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
nitro
alkenyl
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013503921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533846A5 (https=
Inventor
ハンセン、マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham Young University
Original Assignee
Brigham Young University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham Young University filed Critical Brigham Young University
Publication of JP2013533846A publication Critical patent/JP2013533846A/ja
Publication of JP2013533846A5 publication Critical patent/JP2013533846A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013503921A 2010-04-06 2011-04-06 抗転移化合物 Pending JP2013533846A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32132410P 2010-04-06 2010-04-06
US61/321,324 2010-04-06
US32238310P 2010-04-09 2010-04-09
US61/322,383 2010-04-09
US32568210P 2010-04-19 2010-04-19
US61/325,682 2010-04-19
PCT/US2011/031448 WO2011127192A2 (en) 2010-04-06 2011-04-06 Antimetastatic compounds

Publications (2)

Publication Number Publication Date
JP2013533846A true JP2013533846A (ja) 2013-08-29
JP2013533846A5 JP2013533846A5 (https=) 2014-05-22

Family

ID=44763529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013503921A Pending JP2013533846A (ja) 2010-04-06 2011-04-06 抗転移化合物

Country Status (6)

Country Link
US (2) US8481553B2 (https=)
EP (1) EP2555766A4 (https=)
JP (1) JP2013533846A (https=)
AU (1) AU2011237642B2 (https=)
CA (1) CA2794112A1 (https=)
WO (1) WO2011127192A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083866A1 (en) * 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
WO2012097196A1 (en) * 2011-01-12 2012-07-19 Acea Biosciences Inc. Pyrazolopyrimidine derivatives and uses as anticancer agents
JP5955531B2 (ja) * 2011-11-07 2016-07-20 千葉県 抗癌剤
WO2014009891A1 (en) * 2012-07-11 2014-01-16 Piramal Enterprises Limited Heterocyclic compounds for use in the treatment of cancers
AU2014254078A1 (en) 2013-04-19 2015-10-15 Bioventures, Llc Combretastatin analogs
WO2015153635A1 (en) 2014-03-31 2015-10-08 Board Of Trustees Of The University Of Arkansas Disubstituted triazole analogs
WO2016040951A1 (en) * 2014-09-12 2016-03-17 Vanderbilt University Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase
US10329304B2 (en) * 2014-09-12 2019-06-25 Vanderbilt University Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase
EP3303346B1 (en) 2015-05-28 2020-09-16 The Regents of the University of California Tubulin-binding compounds, compositions and uses related thereto
WO2018102766A2 (en) * 2016-12-01 2018-06-07 Oregon State University Small molecule bcl-2 functional converters as cancer therapeutics
WO2018144910A1 (en) 2017-02-02 2018-08-09 Bioventures, Llc Methods of protecting against neurodegeneration
CN106905347B (zh) * 2017-04-18 2019-04-16 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
KR102131331B1 (ko) * 2018-09-19 2020-07-07 연세대학교 산학협력단 항암용 신규 약학 조성물 및 ano1 활성억제제
CN110590806B (zh) * 2019-09-27 2021-10-29 深圳大学 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途
CN111494381B (zh) * 2020-04-30 2023-07-28 南方医科大学 烯基喹啉化合物在制备抗肿瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008369A1 (en) * 1999-03-03 2003-01-09 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases
JP2007508350A (ja) * 2003-10-15 2007-04-05 イーエムテーエム ゲーエムベーハー 異なる細胞に機能的に影響を及ぼし、免疫性疾患、炎症性疾患、神経疾患、およびその他の疾患を治療するための二重のアラニルアミノペプチダーゼおよびジペプチジルペプチダーゼｉｖの阻害剤
JP2007509037A (ja) * 2003-10-09 2007-04-12 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング アシルヒドラゾン誘導体ならびにキナーゼシグナル伝達の阻害、調節および／または調整におけるそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
MXPA06000276A (es) * 2003-07-02 2006-04-07 Sugen Inc Indolinona hidrazidas como inhibidores de c-met.
CA2556025A1 (en) * 2004-02-23 2005-09-09 Sugen, Inc. Method of treating abnormal cell growth using c-met and m-tor inhibitors
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009155362A1 (en) * 2008-06-19 2009-12-23 Ligand Pharmaceuticals Inc. Small molecule hematopoietic growth factor mimetic compounds and their uses
US20130158035A1 (en) 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008369A1 (en) * 1999-03-03 2003-01-09 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases
JP2007509037A (ja) * 2003-10-09 2007-04-12 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング アシルヒドラゾン誘導体ならびにキナーゼシグナル伝達の阻害、調節および／または調整におけるそれらの使用
JP2007508350A (ja) * 2003-10-15 2007-04-05 イーエムテーエム ゲーエムベーハー 異なる細胞に機能的に影響を及ぼし、免疫性疾患、炎症性疾患、神経疾患、およびその他の疾患を治療するための二重のアラニルアミノペプチダーゼおよびジペプチジルペプチダーゼｉｖの阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6015012436; 日消誌，　２０００，　９７，　６８０-６９０ *
JPN6015012438; 日産婦誌，　１９９９，　５１巻，　１１号，　Ｎ-４５５-Ｎ-４５８ *
JPN6015012440; Ｏｎｃｏｇｅｎｅ．　２０００　Ｎｏｖ　２０；１９（４９）：５５８２-９ *
JPN6015012443; Ｔｒｅｎｄｓ　Ｃｅｌｌ　Ｂｉｏｌ．　２００３　Ｊｕｎ；１３（６）：３２８-３５ *

Also Published As

Publication number Publication date
EP2555766A2 (en) 2013-02-13
US20130035348A1 (en) 2013-02-07
EP2555766A4 (en) 2015-06-03
CA2794112A1 (en) 2011-10-13
WO2011127192A2 (en) 2011-10-13
AU2011237642B2 (en) 2014-05-01
US8481553B2 (en) 2013-07-09
WO2011127192A3 (en) 2014-03-27
AU2011237642A1 (en) 2012-10-18
US20130225610A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
JP2013533846A (ja) 抗転移化合物
JP2013536241A (ja) 抗転移化合物
US9597325B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
EP2818170B1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
EP3498278A1 (en) Compounds for treatment of diseases related to dux4 expression
WO2012028233A1 (de) Imidazo [4,5-c]chinoline als dna-pk-inhibitoren
BRPI0808714A2 (pt) Uso de compostos, tais como 4-amino-5-fluoro-3-[6-(4-metil piperazinil-1)- 1h-benzimidazolil-2] quinolinona-(1h)-2 e tautômeros, sais, e misturas dos mesmos no preparo de medicamentos para o tratamento do melanoma
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
KR20160012984A (ko) 벤조푸라논과 인돌 또는 아자인돌 콘쥬게이트 및 그의 제조방법과 용도
EP2906564A1 (en) Treating brain cancer using agelastatin a (aa) and analogues thereof
US10392398B2 (en) Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
JP2008528552A (ja) 新規のインドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
WO2017069913A1 (en) Chalcone compounds
CN101641097A (zh) 黑素瘤的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027